Insider Trading Activity Clovis Oncology, Inc. (NASDAQ:CLVS) – Director Sold 18,450 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Clovis Oncology, Inc. (NASDAQ:CLVS)

James C Blair , Director of Clovis Oncology, Inc. (NASDAQ:CLVS) reportedly Sold 18,450 shares of the company’s stock at an average price of 78.61 for a total transaction amount of $1,450,354.50 SEC Form

Insider Trading History For Clovis Oncology, Inc. (NASDAQ:CLVS)

On 8/16/2012 Edward J Mckinley, Director, bought 9,701 with an average share price of $15.50 per share and the total transaction amounting to $150,365.50.View SEC Filing

On 3/6/2013 Parters Vii L P Domain, Major Shareholder, sold 250,000 with an average share price of $24.59 per share and the total transaction amounting to $6,147,500.00.View SEC Filing

On 6/4/2013 Steven L Hoerter, Insider, sold 10,000 with an average share price of $73.06 per share and the total transaction amounting to $730,600.00.View SEC Filing

On 6/4/2013 Parters Vii L P Domain, Major Shareholder, sold 159,192 with an average share price of $64.58 per share and the total transaction amounting to $10,280,619.36.View SEC Filing

On 6/4/2013 M James Barrett, Director, sold 2,483 with an average share price of $70.80 per share and the total transaction amounting to $175,796.40.View SEC Filing

On 6/5/2013 Andrew R Allen, Insider, sold 22,594 with an average share price of $68.54 per share and the total transaction amounting to $1,548,592.76.View SEC Filing

On 12/5/2013 Thorlef Spickschen, Director, sold 9,000 with an average share price of $56.10 per share and the total transaction amounting to $504,900.00.View SEC Filing

Analyst Ratings For Clovis Oncology, Inc. (NASDAQ:CLVS)
These are 6 Hold Ratings, 10 Buy Ratings .
The current consensus rating for Clovis Oncology, Inc. (NASDAQ:CLVS) is Buy (Score: 2.63) with a consensus target price of $79.50 , a potential (5.16% upside)

Analyst Ratings History For Clovis Oncology, Inc. (NASDAQ:CLVS)

On 8/24/2016 Mizuho Boost Price Target of rating Neutral with a price target of $15.00 to $23.00
On 12/21/2016 WallachBeth Capital Boost Price Target of rating Hold with a price target of $22.00 to $49.00
On 3/28/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $77.00
On 6/19/2017 Chardan Capital Upgraded rating Sell to Neutral with a price target of $36.00 to $50.00
On 6/19/2017 Stifel Nicolaus Boost Price Target of rating Buy with a price target of $86.00 to $125.00
On 6/19/2017 Leerink Swann Boost Price Target of rating Outperform with a price target of $85.00 to $114.00
On 6/20/2017 Morgan Stanley Reiterated Rating Overweight with a price target of $79.00

Recent Trading Activity for Clovis Oncology, Inc. (NASDAQ:CLVS)
Shares of Clovis Oncology, Inc. closed the previous trading session at 75.60 down -1.69 -2.19% with 1,282,831 shares trading hands.